個人化醫療生物標記市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

全球個人化醫療生物標記市場預計到2023 年價值159 億美元，預計將實現顯著成長，2024 年至2032 年複合年成長率預計為15.1%。 、基因組學和蛋白​​質組學的進步以及向客製化醫療保健解決方案的轉變。隨著醫療保健變得更加以患者為中心，個人化醫療生物標記透過實現精確、有針對性的護理而徹底改變了治療方法。基因組定序和分子診斷的重大進展增強了識別疾病特異性生物標記的能力，從而實現了更量身定做的治療策略。製藥公司正在利用這些進步來開發具有更高功效和更少副作用的精準療法，並改善患者的治療效果和依從性。

按生物標記類型細分，市場包括基因組、蛋白質組和代謝生物標記等。基因組生物標記在 2023 年的收入高達 66 億美元，凸顯了它們在疾病檢測、風險評估和治療最佳化方面的重要性。來自基因分析的基因組標記可以深入了解遺傳傾向，並且可以預測患者對特定治療的反應，特別是在腫瘤學等領域。這些見解使醫療保健提供者能夠設計出更有效的針對患者的治療方法，提高治療成功率並改善生活品質。

從應用來看，市場分為早期檢測/篩檢、診斷、治療選擇和監測。到 2023 年，診斷領域將佔據 34.1% 的佔有率，對於早期、準確的疾病檢測仍然至關重要。利用遺傳、蛋白質組和代謝組等各種生物標記，個人化診斷為臨床醫生提供了有關疾病階段和潛在治療反應的寶貴見解。這對於管理腫瘤學、心臟病學和神經病學的病情尤其重要，及時介入是關鍵。

在美國，個人化醫療生物標記市場預計將以15% 的複合年成長率成長，到2032 年將達到211 億美元。 這種成長得益於該國先進的醫療基礎設施、大量的研發投資和 這種成長得益於該國先進的醫療基礎設施、大量的研發投資和積極採用精準醫療。聯邦措施正在加速研究並促進資料整合，而慢性病的流行繼續推動生物標記的需求。此外，頂級製藥和生物技術公司與學術和政府機構之間的合作正在刺激生物標記開發的創新。患者意識的提高和對個性化治療選擇的需求推動了這一趨勢，診斷和伴隨治療的利用率不斷提高，以提高治療效果並最大限度地減少不良反應。向治療的不斷發展，個人化醫學生物標記市場有望大幅擴張重塑患者護理，提高治療效率並滿足患者個別需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 基因組學和蛋白​​質組學的進展
    • 慢性病盛行率上升
    • 標靶治療的需求不斷成長
  • 產業陷阱與挑戰
    • 開發成本高
    • 監理複雜性
• 成長潛力分析
• 監管環境
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：依生物標記類型，2021-2032 年

• 主要趨勢
• 基因組
• 蛋白質體學
• 代謝
• 其他生物標記類型

第 6 章：市場估計與預測：按應用分類，2021-2032 年

• 主要趨勢
• 早期發現/篩檢
• 診斷
• 治療選擇
• 監控
• 其他應用

第 7 章：市場估計與預測：依疾病適應症，2021-2032 年

• 主要趨勢
• 腫瘤學
• 神經病學
• 糖尿病
• 自體免疫疾病
• 心臟病學
• 其他適應症

第 8 章：市場估計與預測：依最終用途，2021-2032 年

• 主要趨勢
• 醫院和診所
• 製藥和生物技術公司
• 診斷實驗室
• 其他最終用戶

第 9 章：市場估計與預測：按地區，2021-2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• MEA
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 10 章：公司簡介

• Abbott Laboratories
• Bio-Rad Laboratories
• Danaher
• EKF Diagnostics Holdings
• F. Hoffmann-La Roche
• Illumina
• Lifesign
• Merck
• Myriad Genetics
• QIAGEN
• Signosis
• Singulex
• Thermo Fisher Scientific

The Global Personalized Medicine Biomarkers Market, valued at USD 15.9 billion in 2023, is set for remarkable growth with a projected CAGR of 15.1% from 2024 to 2032. This market expansion is driven by increasing chronic disease rates, advancements in genomics and proteomics, and the shift toward customized healthcare solutions. As healthcare becomes more patient-centered, personalized medicine biomarkers revolutionize treatment by enabling precise, targeted care. Significant progress in genomic sequencing and molecular diagnostics has enhanced the ability to identify disease-specific biomarkers, enabling more tailored treatment strategies. Pharmaceutical companies are harnessing these advancements to develop precision therapies with greater efficacy and reduced side effects and improve patient outcomes and adherence.

Segmented by biomarker type, the market includes genomic, proteomic, and metabolic biomarkers, among others. Genomic biomarkers led with a substantial USD 6.6 billion in revenue in 2023, underscoring their importance in disease detection, risk evaluation, and treatment optimization. Genomic markers, derived from gene analysis, provide insights into genetic predispositions and can predict how patients respond to specific treatments, particularly in fields like oncology. These insights allow healthcare providers to devise more effective, patient-specific therapies, bolstering treatment success rates and improving quality of life.

In terms of applications, the market is divided into early detection/screening, diagnosis, treatment selection, and monitoring. The diagnostic segment held a 34.1% share in 2023 and remains essential for early and accurate disease detection. Leveraging various biomarkers, such as genetic, proteomic, and metabolomic, personalized diagnostics offer clinicians valuable insights into disease stages and potential therapeutic responses. This is especially critical in managing conditions in oncology, cardiology, and neurology, where timely intervention is key.

In the U.S., the personalized medicine biomarkers market is anticipated to grow at a 15% CAGR, reaching USD 21.1 billion by 2032. This growth is supported by the country's advanced healthcare infrastructure, significant R&D investments, and proactive adoption of precision medicine. Federal initiatives are accelerating research and fostering data integration, while the prevalence of chronic diseases continues to drive biomarker demand. Additionally, collaboration between top pharmaceutical and biotech companies, with academic and government institutions is spurring innovations in biomarker development. Rising patient awareness and demand for personalized treatment options fuel this trend, with diagnostics and companion therapeutics seeing increased utilization to enhance treatment outcomes and minimize adverse effects.Overall, the personalized medicine biomarkers market is positioned for substantial expansion, as precision diagnostics and targeted therapies continue to reshape patient care, making treatment more efficient and aligned with individual patient needs.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advances in genomics and proteomics
    • 3.2.1.2 Rising prevalence of chronic diseases
    • 3.2.1.3 Growing demand for targeted therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High development costs
    • 3.2.2.2 Regulatory complexities
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Biomarker Type, 2021-2032 ($ Mn)

• 5.1 Key trends
• 5.2 Genomic
• 5.3 Proteomics
• 5.4 Metabolic
• 5.5 Other biomarker types

Chapter 6 Market Estimates & Forecast, By Application, 2021-2032 ($ Mn)

• 6.1 Key trends
• 6.2 Early detection/screening
• 6.3 Diagnosis
• 6.4 Treatment selection
• 6.5 Monitoring
• 6.6 Other applications

Chapter 7 Market Estimates & Forecast, By Disease Indication, 2021-2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Neurology
• 7.4 Diabetes
• 7.5 Autoimmune diseases
• 7.6 Cardiology
• 7.7 Other indications

Chapter 8 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Pharmaceutical and biotechnology companies
• 8.4 Diagnostic labs
• 8.5 Other end users

Chapter 9 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Bio-Rad Laboratories
• 10.3 Danaher
• 10.4 EKF Diagnostics Holdings
• 10.5 F. Hoffmann-La Roche
• 10.6 Illumina
• 10.7 Lifesign
• 10.8 Merck
• 10.9 Myriad Genetics
• 10.10 QIAGEN
• 10.11 Signosis
• 10.12 Singulex
• 10.13 Thermo Fisher Scientific